Efficacy of SEROQUEL in Selective Serotonin Reuptake Inhibitors (SSRI)-Resistant Major Depressive Disorder

• Status: Completed
• Trial end date: 2007-11-01
• Target enrollment: 0
• Participant gender: All

Summary

An open-label, non-comparative, multi-centre, phase II prospective trial to assess the efficacy of Quetiapine fumarate augmentation of selective serotonin reuptake inhibitors (SSRIs) in SSRI-resistant major depressive disorder.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Quetiapine Fumarate; Serotonin; Serotonin Uptake Inhibitors

Criteria

Inclusion Criteria:

• Inform consent

• Male and female, age between 18 and 65 years.

• Naïve to any atypical antipsychotic

• A diagnosis of major depressive disorder

Exclusion Criteria:

• No use of fluvoxamine

• Patients with a history of bipolar I or II disorder

• Diagnosis of psychotic major depression disorder